Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Single-Center, Randomized Controlled Trial of Transcoronary Radiofrequency Ablation Versus Transcoronary Alcohol Ablation for Hypertrophic Obstructive Cardiomyopathy

16 de noviembre de 2026 actualizado por: Ligang Ding

Patients with hypertrophic obstructive cardiomyopathy (HOCM) require septal reduction therapy to relieve left ventricular outflow tract obstruction (LVOTO). Septal myectomy is an open surgical procedure that resects hypertrophied septal myocardium to reduce outflow tract obstruction. However, it is associated with relatively substantial trauma. Some patients cannot tolerate surgery due to comorbidities or decline open-chest surgery.

Transcoronary alcohol ablation is a classic minimally invasive septal reduction therapy with a clinical history of nearly 30 years. Alcohol ablation induces myocardial injury via a chemical agent to reduce septal hypertrophy, widen the left ventricular outflow tract, lower the systolic pressure gradient, and improve clinical symptoms. It serves as a minimally invasive alternative to surgery. Nevertheless, the efficacy of this technique is highly dependent on the anatomical features of septal branches. Suboptimal outcomes may occur in some patients owing to variable septal branch anatomy. In addition, due to the high myocardial permeability of alcohol, atrioventricular block occurs in approximately 20% of patients after the procedure.

In recent years, transcoronary radiofrequency ablation has emerged as a novel minimally invasive septal reduction approach in clinical practice. For radiofrequency ablation, a microcatheter is advanced over a coronary guidewire into the septal branch. The proximal end of the guidewire is connected to a radiofrequency ablation generator, and myocardial ablation is delivered around the guidewire tip. Occlusion of the septal branch may further potentiate the ablative effect. This technique is less limited by anatomical variations of septal branches, features a shorter learning curve, and may have less impact on the conduction system. Compared with alcohol ablation, it enables more precise ablation with potentially superior safety. Both minimally invasive strategies achieve an obstruction relief rate exceeding 90%. To date, head-to-head data comparing the efficacy and safety profiles of these two minimally invasive therapies remain absent. Therefore, this randomized controlled trial is designed to compare the efficacy and safety of transcoronary alcohol ablation versus transcoronary radiofrequency ablation for hypertrophic obstructive cardiomyopathy.

You will be randomized in a 1:1 ratio to either the transcoronary alcohol ablation group or the transcoronary radiofrequency ablation group using a block randomization schedule. The probability of assignment to either group is 50%.

After randomization, cardiopulmonary exercise testing data, laboratory results and echocardiographic data will be collected at baseline, and the impact of cardiomyopathy on your quality of life will be assessed. Procedures in both groups will be performed by designated operators of the study team following standardized protocols. You will be blinded to the assigned treatment. In both groups, SonoVue will be injected into the coronary septal branch intraoperatively, and transthoracic echocardiography will be used to confirm that the ablation target is the critical site responsible for obstruction to ensure precise treatment. In the alcohol ablation group, 2-3 mL of absolute alcohol will be injected into the septal branch. In the radiofrequency ablation group, the guidewire will be connected to the radiofrequency generator; ablation energy will be set at 30-40 W, with 3 ablation applications of 30 seconds each at a single target site. Intraoperative electrocardiogram, heart rate, blood pressure and symptoms will be closely monitored, and the pressure gradient will be measured in real time using catheters and ultrasound. All patients will receive standardized medical therapy after the procedure. You will attend an outpatient follow-up visit at 3 months post-procedure, where repeat cardiopulmonary exercise testing, laboratory tests and echocardiography will be performed, and the post-procedure impact of cardiomyopathy on your quality of life will be re-evaluated. The primary endpoint of this study is the improvement in peak oxygen consumption on cardiopulmonary exercise testing at 3 months after treatment. No blood or tissue samples will be collected or stored for this study.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

80

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100037
        • Reclutamiento
        • Fuwai Hospital, Chinese Academy of Medical Sciences
        • Contacto:
          • Ethics committee office
          • Número de teléfono: 010-88396282
          • Correo electrónico: fuwailunli@fuwai.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • 1. Age > 18 years; 2. Diagnosis of hypertrophic obstructive cardiomyopathy (HOCM), with resting LVOTG > 50 mmHg measured by echocardiography or cardiac catheterization; 3. Persistent symptoms despite treatment with maximally tolerated doses of beta-blockers or calcium channel blockers (CCBs); 4. New York Heart Association (NYHA) functional class II or higher; 5. Echocardiographic confirmation that the obstruction originates from the interventricular septum at the left ventricular outflow tract; 6. Suitable septal branch visualized on coronary angiography, with contrast echocardiography confirming its perfusion territory corresponds to the target ablation site; 7. Interventricular septal thickness < 30 mm; 8. High surgical risk or explicit patient refusal of septal myectomy; 9. Ability to understand the study purpose, voluntary participation, and provision of written informed consent.

Exclusion Criteria:

  • Patients with severe mitral regurgitation secondary to organic mitral valve disease or other cardiac structural abnormalities requiring surgical intervention; Patients with significant stenosis of the left anterior descending coronary artery requiring percutaneous coronary intervention; Patients with bradyarrhythmia who have an indication for permanent pacemaker implantation; Patients with prior history of septal reduction therapy; Patients receiving myosin inhibitor therapy; Patients with severe hepatic or renal dysfunction; Patients with contraindications to coronary angiography and percutaneous interventional procedures; Patients with severe heart failure or cardiogenic shock who cannot maintain a supine position; Patients with a history of anaphylactic shock induced by contrast media; Patients considered ineligible for enrollment for other reasons at the investigator's discretion; Patients with pre-existing complete left bundle branch block at baseline.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: transcoronary radiofrequency ablation

Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVO

Both groups received SonoVue injection into the septal branch, and transthoracic echocardiography was used to confirm that the ablation site was the critical lesion responsible for obstruction. In the TCRFA group, a microcatheter was advanced over a coronary guidewire into the septal branch; the proximal end of the guidewire was connected to a radiofrequency ablation generator, and myocardial ablation was delivered around the guidewire tip. The ablation power was set at 30-40 W, with three applications of 30 seconds each at a single target site. Intraoperatively, electrocardiogram, heart rate, blood pressure and symptoms were closely monitored in both groups, and the left ventricular outflow tract gradient (LVOTG) was measured in real time via catheter and ultrasound. For patients in the TCRFA group whose post-treatment LVOTG failed to meet the criteria for obstruction relief, supplementary endocardial ablation would be performed intraoperatively to achieve the target reduction of LVOT

Otros nombres:
  • TCRFA
Comparador activo: transcoronary alcohol ablation

SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound.

SonoVue is injected into the septal branch, and transthoracic echocardiography is used to confirm that the ablation site is the critical site causing obstruction. In the ASA group, 2-3 mL of absolute alcohol is injected into the septal branch. Intraoperatively, the patient's electrocardiogram, heart rate, blood pressure and symptoms are closely monitored, and LVOTG is measured in real time using catheters and ultrasound.

Otros nombres:
  • asa

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
absolute improvement in peak VO₂
Periodo de tiempo: baseline,3 months

Cardiopulmonary exercise testing is performed at baseline and at 3 months after the procedure to measure peak VO₂. The absolute improvement in peak VO₂ is defined as the post-procedure value minus the baseline value.

baseline,3 months
ncidence of new-onset complete left or right bundle branch block and/or permanent pacemaker implantation
Periodo de tiempo: baseline,3 months

The incidence of new-onset complete left bundle branch block, complete right bundle branch block, and/or permanent pacemaker implantation occurring from the time of the index procedure up to the 3-month post-procedure follow-up.

baseline,3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Intraprocedural immediate reduction of LVOTG meeting criteria for obstruction relief
Periodo de tiempo: Intraoperatively

Proportion of participants with immediate intraprocedural LVOTG reduction that satisfies the predefined criteria for relief of left ventricular outflow tract obstruction.

Intraoperatively
Response rate of peak VO₂ at 3 months post-procedure
Periodo de tiempo: Baseline and 3 months after the procedure

Response rate is defined as the proportion of participants achieving a predefined improvement in peak VO₂ measured by cardiopulmonary exercise testing at 3 months post-procedure versus baseline.

Baseline and 3 months after the procedure
Reduction of LVOTG meeting obstruction relief criteria at 3 months post-procedure
Periodo de tiempo: Baseline and 3 months after the procedure

Proportion of participants whose LVOTG reduction meets the predefined obstruction relief criteria at 3-month follow-up.

Baseline and 3 months after the procedure
Absolute reduction of basal septal thickness
Periodo de tiempo: Baseline and 3 months after the procedure

Absolute difference in basal interventricular septal thickness between baseline and 3 months post-procedure, assessed by echocardiography.

Baseline and 3 months after the procedure
6-minute walk test distance
Periodo de tiempo: Baseline and 3 months after the procedure

Distance covered during the 6-minute walk test at baseline and at 3 months post-procedure.

Baseline and 3 months after the procedure
Canadian Cardiovascular Society (CCS) Angina Grade
Periodo de tiempo: Baseline and 3 months after the procedure

Change in Canadian Cardiovascular Society angina grade from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Quality of life score
Periodo de tiempo: Baseline and 3 months after the procedure

Change in generic quality-of-life score from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Kansas City Cardiomyopathy Questionnaire (KCCQ) score
Periodo de tiempo: Baseline and 3 months after the procedure

Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score from baseline to 3 months post-procedure.

Baseline and 3 months after the procedure
Improvement in New York Heart Association (NYHA) functional class
Periodo de tiempo: Baseline and 3 months after the procedure

Proportion of participants with improvement in New York Heart Association functional class at 3 months post-procedure compared with baseline.

Baseline and 3 months after the procedure

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

16 de noviembre de 2026

Finalización primaria (Estimado)

30 de septiembre de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

16 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Publicado por primera vez (Actual)

20 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data will not be shared to ensure patient confidentiality and comply with local institutional data protection policies.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir